

March 7, 2018

Tatsuo Higuchi

President and Representative Director

Otsuka Holdings Co., Ltd.

2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo

Dear Shareholders:

**Partial Correction to the Notice for the Calling of
the 10th Annual Shareholders Meeting (for FY 2017)**

Otsuka Holdings Co., Ltd. (the “Company”) hereby reports that there is a part to be corrected in the Business Report attached to the Notice for the Calling of the 10th Annual Shareholders Meeting (the “Notice”) issued on March 7, 2018. The Company therefore decided to make correction to the said part as described below.

Corrected part:

Development status of OPC-34712 *REXULTI* (brexpiprazole) in pipeline information on page 21 of the Notice

<Before correction>

Category	Development Code <i>Brand name</i> (Generic name)	Indication / Dosage form	Development status					
			JP		U.S.		EU	
			Phase III	Filed	Phase III	Filed	Phase III	Filed
Central nervous system and neurology	OPC-34712 <i>REXULTI</i> (brexpiprazole)	Major depressive disorder / Oral					•	
		Schizophrenia / Oral		■				•
		Agitation associated with Alzheimer-type dementia / Oral			•		•	
		Bipolar I disorder / Oral			•		•	

<After correction>

Category	Development Code <i>Brand name</i> (Generic name)	Indication / Dosage form	Development status					
			JP		U.S.		EU	
			Phase III	Filed	Phase III	Filed	Phase III	Filed
Central nervous system and neurology	OPC-34712 <i>REXULTI</i> (brexpiprazole)	Major depressive disorder / Oral					•	
		Schizophrenia / Oral		■				•
		Agitation associated with Alzheimer-type dementia / Oral			•		•	
		Bipolar I disorder / Oral			•		•	